High-dose cyclosporin with etoposide in children with solid tumours
Author Information
Author(s): G Bisognol, F Cowie, A Boddy, HD Thomas, G Dick, CR Pinkerton
Primary Institution: Royal Marsden NHS Trust/Institute of Cancer Research
Hypothesis
Can high-dose cyclosporin enhance the effectiveness of etoposide in treating children with recurrent or refractory solid tumours?
Conclusion
The combination of high-dose cyclosporin and etoposide may enhance drug sensitivity in children with solid tumours, but the etoposide dose should be halved to avoid toxicity.
Supporting Evidence
- Four patients achieved a partial response to the treatment.
- Significant hypertension was observed in six courses.
- Hyperbilirubinaemia was present in 25 of 32 courses but was of short duration.
- Acute toxicity was less common with the continuous infusion compared to the shorter regimen.
Takeaway
This study tested a new treatment for kids with tough cancers by using a special medicine called cyclosporin to help another medicine, etoposide, work better.
Methodology
Eighteen children with recurrent or refractory tumours were treated with high-dose cyclosporin and etoposide, with pharmacokinetic profiles assessed.
Limitations
The study was small and focused primarily on toxicity rather than effectiveness.
Participant Demographics
Participants were children aged 4.4 to 20.7 years, with a median age of 13.6 years; 13 were male.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website